Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M17MO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NIjCe3IzPTl4MEK4Ni=>
KellyCis83 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXhTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= NH;S[ZAzPTl4MEK4Ni=>
SK-N-AS NWXKTGtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NWT3PIc2OjV7NkCyPFI>
SK-N-ASCis24 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG3RnlKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN NVvafHJkOjV7NkCyPFI>
U87 NW\Xe|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPxPJhpOC13MDFOwG0> NHv1Vms1QCCq M2ruVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw MlvaNlU4PTB{N{O=
HCT116 NIC2W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf3Vng{OC53LUKuOUDPxE1? Mn;LOFjDqGkEoB?= M2\QeGlEPTB;MT63N:KhyrIEoECuNlHDqM7:TR?= MknhNlU4PDZ5NkO=
HT-29 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuxTZB{OC53LUKuOUDPxE1? NWr4OI1OPDkEoHlCpC=> NUnY[HpsUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= MnHGNlU4PDZ5NkO=
Caco2 M1Pac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;OVJpXOC53LUKuOUDPxE1? MXe0POKhcMLi MW\JR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? Mn:wNlU4PDZ5NkO=
COLO 205 NYXIflRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fhcVAvPS1{LkWg{txO M13jTVQ5yqCqwrC= NIOzTIpKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= NVf2Z3NEOjV5NE[3OlM>
SW480 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWwMlUuOi53IN88US=> NYHKWJRWPDkEoHlCpC=> MknjTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M4XlZVI2PzR4N{[z
HEK293T M3;jNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;NfFEuPSEQvF2= MVy0POKhcMLi M3H3cGlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= NH\kdpUzPTd2Nke2Ny=>
Hep3B  MUjGeY5kfGmxbjDBd5NigQ>? NYT5b4ExOTBizszN MmfyOFjDqGkEoB?= M2nm[JJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> M{nJUlI2PjN|NU[0
Hep3B  MUnGeY5kfGmxbjDBd5NigQ>? MYewMlEuOTBizszN MYGyOEBp MlLSd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D NIDKVpczPTZ|M{W2OC=>
HEK293 NGS5PWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK5NYp2UUN3ME23MlE1yqEEsdMgNE4{PsLizszN NEXBRnIzPTZyM{GyNi=>
DU145 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jOUGlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= M4XqNlI2PjB|MUKy
HCT15 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwU2lEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= M2TWclI2PjB|MUKy
T47D NX7CSYhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq3eY53UUN3ME2zMlE5yqEEsdMgNE4yOcLizszN MYqyOVYxOzF{Mh?=
SMMC-7721 NHPaU5pHfW6ldHnvckBCe3OjeR?= M2r6TlQxKM7:TR?= MmPPOFghcA>? NWDNZo5TTE2VTx?= NX3MdFhTcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? MXGyOVU1PDN4MR?=
MDA-MB-231 NHLOd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHKO|LDqGh? NF\iR2FKSzVyPUKxMlLDqMLzwrC0MlLDqM7:TR?= Mk\kNlU1QDZ{MUm=
MCF-7 M4f3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NuKhcA>? MXHJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? M3HQNlI2PDh4MkG5
Jurkat MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvwNYw4OsLiaB?= Mlj4TWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? NXrzd5NmOjV2OE[yNVk>
HeLa MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[2O|LDqGh? NHq1T5JKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP M1r3V|I2PDh4MkG5
MCF7  M3n5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1MVExOCEQvF2= M{PlSFch\A>? NVTMPIRvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NW\3[mY2OjV2N{K2NVk>
K562 NXnDSJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPtVJE4OsLiaB?= NV7SUppxUUN3ME2wMlI6yqEQvF2= MUKyOVI5OjZ3Mx?=
K/VP.5 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTjO|LDqGh? NH[4WpJKSzVyPUSuPeKh|ryP M{\Wd|I2Ojh{NkWz
SH-EP  NHjSXZZHfW6ldHnvckBCe3OjeR?= MojMNlDDqM7:Zz;tcC=> Mne3NlTDqGh? NHyxdVVqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\W6mb3flco92eyCGRWDQ NUO0[IFsOjV{NkG5PFE>
SCC25 NYnyb5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqyOOKhcA>? M1v6O2lEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= NVHSe3JrOjV{MkC3Nlk>
CAL27 NHrxfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4TIMzPMLiaB?= MUHJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? MmPXNlUzOjB5Mkm=
FaDu Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqyOOKhcA>? MXTJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP MVGyOVIzODd{OR?=
SCC25 M4\CbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHhOFjDqGh? Mnn4TWM2OD1{MD64OuKhyrIEoEGuNFfDqM7:TR?= NF71ZoQzPTJ{MEeyPS=>
CAL27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD3OFjDqGh? MmHKTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= MXqyOVIzODd{OR?=
FaDu NHLiVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrTZnp2PDkEoHi= M3Xxc2lEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= MYqyOVIzODd{OR?=
SCC25 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWO3NuKhcA>? MkLETWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NUK2PIg5OjV{MkC3Nlk>
CAL27 NUnXfmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3NuKhcA>? MlLWTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP NIXNSWQzPTJ{MEeyPS=>
FaDu NVXrRXFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX6O|LDqGh? NYS3VphqUUN3ME21MlAzyqEEsdMgNU4yPcLizszN MlrWNlUzOjB5Mkm=
MCF-7 NILMd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;oOGs1QMLiaNMg NWjTeXdTTE2VTx?= Ml:2TWM2OD15LkNCpOKyyqByLklCpO69VQ>? NHu5W2MzPTJzNkO3PC=>
T-47D NXLJ[lN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrhSZBVPDkEoHlCpC=> M4DRbWROW09? NEW0VFNKSzVyPUeuO:KhyrIEoECuO:Kh|ryP NX\lT5N[OjV{MU[zO|g>
MDA-MB-231 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;jZ45GPDkEoHlCpC=> MnHCSG1UVw>? M4q1fGlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP MYKyOVIyPjN5OB?=
DU145 NX[2dlNlSXCxcITvd4l{KEG|c3H5 NXXRTmtQOTBvMUCwJO69VQ>? MXe4JIg> NYXFXXF[TE2VTx?= M1y1OIlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MmDMNlUyPDl4OEG=
DU145 stem-like MnrkRZBweHSxc3nzJGF{e2G7 M1Hkb|ExNTFyMDFOwG0> NV\KbYtlQCCq MWnEUXNQ NHLaUVhqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWTHZ4I5OjVzNEm2PFE>
DU145 NVfWOFZkTnWwY4Tpc44hSXO|YYm= Mn7RNVAuOTByIN88US=> MUGyJIg> MWXEUXNQ MknqbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnW5NlUyPDl4OEG=
DU145 stem-like MXvGeY5kfGmxbjDBd5NigQ>? MmHwNVAuOTByIN88US=> MV:yJIg> MYPEUXNQ Mn:5bY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4fyWVI2OTR7Nkix
UW228-3 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMlAyNTNyMDFOwG0> MXi0PEBp NVn2PVlITE2VTx?= MkDETWM2OD1yLkm5xsDPxE1? NITnOYYzPTFzOUG4OS=>
NSCs NEnDfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6wMlAyNTNyMDFOwG0> NXeyfFJwPDhiaB?= MXvEUXNQ M{Wz[mlEPTB;MD6zMVPDqM7:TR?= MoX2NlUyOTlzOEW=
MKL-1  NHHIXohHfW6ldHnvckBCe3OjeR?= NHLGe2MyOC1zMECwJI5O NFfYPIU1KGR? MV7pcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? MkmyNlUyOTZ5NUS=
MCF7 EV MXjGeY5kfGmxbjDBd5NigQ>? M{\xdVExNTFyMDFOwG0> NYD5Z|Q{OuLCiXi= M4m5W4lv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MnTiNlUxQDh{MEO=
MCF 7BMI1 MX3GeY5kfGmxbjDBd5NigQ>? M2f5OFExNTFyMDFOwG0> M4fqcVLjiImq NILGbnNqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? M2LCWlI2ODh6MkCz
MCF7 EV NWrSPGlUTnWwY4Tpc44hSXO|YYm= M2KwcVExNTFyMDFOwG0> NWWxdHVCOuLCiXi= M3G0R2VVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MVOyOVA5QDJyMx?=
MCF7 BMI1 NGHLfmxHfW6ldHnvckBCe3OjeR?= MnizNVAuOTByIN88US=> Ml3GNwKBkWh? MXLFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= Mn\yNlUxQDh{MEO=
HepG2 NUf0WWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrEUXNQyqB? M1PEdmlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= NXPwS3ZIOjVyN{izNVE>
MOLT-3 NV\EUW1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuwd3JFVVORwrC= NFO0cZhKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> NHHZcYgzPTB5OEOxNS=>
HT1080 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPNNU0yODBizszN MYO0M|I1NzR6IHi= NVLWcWtKTE2VT9Mg M4jOWYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MYWyOVA4QDB4NB?=
HT1080 NF\QN|dHfW6ldHnvckBCe3OjeR?= NE\sZYExNjByMEGtNVAxKM7:TR?= Mor5NU0zPCCq NXXMO|NiTE2VT9Mg M{HBVYlv\HWlZYOgdE1xPTNqc3XyNVUqKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NVq0eWVxOjVyN{iwOlQ>
HT1080 M4fKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrRNE4xODBzLUGwNEDPxE1? M{\YXFI1KGh? NF7tRoJFVVORwrC= NHj0UWJk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz NGPs[|UzPTB5OEC2OC=>
HD-MY-Z NV:wUFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfKeJAzPC92OD:3NkBp MUXJR|Ux97zgMUCwJO69VQ>? M4XZNVI2ODR6MkO2
DOHH-2 M1Hkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljTNlQhcA>? NWnNTndCUUN3MP-8olExOCEQvF2= MnjiNlUxPDh{M{[=
DOHH-2 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTHZVVpPDhiaB?= M1;X[WlEPTB;MUmuPeKh|ryP NHW1dmYzPTB2OEKzOi=>
DOHH-2 M{fXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTD[HpEPzJiaB?= MmDsTWM2OD13wrFOwG0> NGnmOVgzPTB2OEKzOi=>
REH M4ftTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKNlQhcA>? MkPJTWM2OD1yLkCyO:Kh|ryP MknJNlUxPDh{M{[=
REH MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonPOFghcA>? Mnm1TWM2OD1yLkCxOOKh|ryP Ml[4NlUxPDh{M{[=
REH NX23T2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrNSHFCPzJiaB?= NXz4N5lpUUN3ME2wMlAyPcLizszN NWPveGd3OjVyNEiyN|Y>
HH NITVWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzhO5BmOjRiaB?= MmP5TWM2OD1zMESuO:Kh|ryP NHrFdoUzPTB2OEKzOi=>
HH M3;ZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7jUZFEPDhiaB?= NITLZVFKSzVyPUS4MlbDqM7:TR?= MkPYNlUxPDh{M{[=
HH MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu3NkBp NV;MR25IUUN3ME2xOE44yqEQvF2= M1X1R|I2ODR6MkO2
HuT-78 NF64NpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjnNlQhcA>? MlqzTWM2OD17LkRCpO69VQ>? NWGzZodWOjVyNEiyN|Y>
HuT-78 M4CxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW3OFghcA>? Mk\WTWM2OD12LkRCpO69VQ>? NELOcJQzPTB2OEKzOi=>
HuT-78 M2j0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3NkBp Ml;5TWM2OD12LkNCpO69VQ>? NELYVlczPTB2OEKzOi=>
OPM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\3NlQhcA>? NWfITJVTUUN3ME2yOE4yyqEQvF2= NVXjUGxLOjVyNEiyN|Y>
OPM-2 M4Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfpOFghcA>? MVrJR|UxRTUEoN88US=> MXyyOVA1QDJ|Nh?=
OPM-2 NH61[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPuUHpZPzJiaB?= Mof5TWM2OD1zLkRCpO69VQ>? NXPOPGNjOjVyNEiyN|Y>
RPMI-8226 M4\xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XGRlI1KGh? NVHZc2tNUUN3ME2xNFYvPsLizszN MnPKNlUxPDh{M{[=
RPMI-8226 M{TBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi0PEBp MYjJR|UxRTlzLkJCpO69VQ>? NEW5UpozPTB2OEKzOi=>
RPMI-8226 M4HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TTO|czKGh? MYrJR|UxRTF2LkpCpO69VQ>? NV3QdZRyOjVyNEiyN|Y>
U-266 NU\ofXpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULDfXozOjRiaB?= MXTJR|UxRTh4LkNCpO69VQ>? NV7kSlFjOjVyNEiyN|Y>
U-266 NV\OcW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrFTI1sPDhiaB?= M33hSWlEPTB;NkiuOOKh|ryP MlexNlUxPDh{M{[=
U-266 NHfKSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOyeW1YPzJiaB?= MXHJR|UxRTJ5LkVCpO69VQ>? M{LIXlI2ODR6MkO2
Kelly NEDBdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\KSWZWOC1zMDFOwG0> NUXGd2FGPzMEoHi= MUfJR|UxRTFwNUG4xsDPxE1? NV:zU|VxOjVyMEi5NFA>
SH-SY5Y  NFXvNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6wMVExKM7:TR?= M2TZbVczyqCq M135UGlEPTB;MD63OVTDqM7:TdMg M1jKTFI2ODB6OUCw
SK-N-AS NF;qfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj2NE0yOCEQvF2= NILkbHI4OsLiaB?= M2XaZWlEPTB;MT63NVLDqM7:TdMg MXKyOVAxQDlyMB?=
SK-N-DZ NVjRfoJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHNV3YxNTFyIN88US=> NETkTlc4OsLiaB?= M3PDd2lEPTB;NT60PFXDqM7:TR?= Mom1NlUxODh7MEC=
HepG2 NF;SR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToOFjDqGh? NIW4W4NFVVORwrC= NILYc5dKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN MVKyOFk6PjF|Nh?=
A549 NGLicG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4OFjDqGh? MkTxSG1UV8Li NEnDfopKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NVm1ZpRlOjR7OU[xN|Y>
MCF7 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jIV|Q5yqCq MY\EUXNQyqB? MnXITWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= M122dlI1QTl4MUO2
HL-60  NITub5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojLO|LDqGh? NVPoSlFiUUN3ME2wMlEz6oDHzszN MmL5NlQ6QTNyMUS=
HL-60[R] M125fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjLVZREPzMEoHi= MY\JR|UxRTNwMUNihKXPxE1? NV\TTpA1OjR7OUOwNVQ>
MIAPACA MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULoRmIxT0l3ME2xMlMhyrFiMD6wN{DPxE1? MUKyOFk2Ozh{MR?=
MCF-7 M2KwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK3S2k2OD1yLkK1JOKyKDBwMTFOwG0> MWWyOFk2Ozh{MR?=
HeLa MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLHTVUxRTBwNkSgxtEhOC52IN88US=> MnHaNlQ6PTN6MkG=
MO59K  M1T2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlPJc4KGR? MUDJR|UxRTBwMUhihKXPxE1? NXHYbG43OjR7NUO1OlE>
MO59J MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHVO{Bl NWP1NWVGUUN3ME2wMlHjiIYQvF2= NVyzc4NXOjR7NUO1OlE>
ME 180 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfORpM2PDkEoHlCpC=> NH3UdJVKSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= M1LhSlI1QTV|MEK3
MCF-7 M1PsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzFO3Y1QMLiaNMg M4DqW2lEPTB;MkOuPUDDuSByLkRihKXPxE1? M{mzOVI1QTV|MEK3
HeLa M{T6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LocFQ5yqCqwrC= MXnJR|UxRTRwN{GgxtEhOS524pEF{txO Mk\UNlQ6PTNyMke=
MDA-MB-453 M3vCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:wbFhyPDkEoHlCpC=> M3SzXGlEPTB;MUKuOUDDuSByLki15qCG|ryP NVPZXJdIOjR7NUOwNlc>
MDA-MB-231 M2XibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLsOFjDqGkEoB?= NHy3c5hKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= NH3Fb|EzPDl3M{CyOy=>
PC-3 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37lT|Q5yqCqwrC= NUGzbpNnUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= M37FblI1QTV|MEK3
HT-29 NXXZUHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzlOFjDqGkEoB?= NEPURndKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= NGLTeWgzPDl3M{CyOy=>
BGC-823 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn3OFjDqGkEoB?= NGHK[4RKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= M3uxPFI1Pzl|OEe3
HeLa NGrhbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO0POKhcMLi NHrvZlJKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NX\Hd3h3OjR5OUO4O|c>
A549 NGjuVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[0POKhcMLi MkiwTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MVGyOFc6Ozh5Nx?=
HK-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr2U|M{PDkEoHlCpC=> MnPDTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? MmT4NlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03669783 Not yet recruiting Childhood Renal Tumor Assistance Publique Hopitaux De Marseille January 1 2019 Phase 3
NCT03742115 Not yet recruiting Hemophagocytic Lymphohistiocytosis Beijing Friendship Hospital December 1 2018 Phase 3
NCT03711305 Not yet recruiting Extensive-stage Small Cell Lung Cancer Jiangsu HengRui Medicine Co. Ltd. December 2018 Phase 3
NCT03579927 Not yet recruiting CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 2018 Phase 1|Phase 2
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID